Vnitr Lek 2005, 51(7-8):854-860

Thrombocytopenic purpuras

P. Salaj
Ústav hematologie a krevní transfuze, Praha, ředitel prof. MUDr. Pavel Klener, DrSc.

Thrombocytopenic purpura represents a heterogeneous group of diseases which is characterized by bleeding tendency and a low number of platelets. In general, the risk of bleeding increases with a decreased number of platelets. However, the patient prognosis depends more on the type and cause of disease than on platelet numbers. The detailed differential diagnosis of thrombocytopenia is very important because the reduced number of platelets is only one of the symptoms associated with other diseases. Pathophysiological etiology of thrombocytopenias is characterized by low platelet production, higher platelet destruction in blood stream or sequestration of platelet in reticulo-endothelial system. Consumptive non-autoimmune thrombocytopenias are the most risky from the group of thrombocytopenic purpura. They represent high risk of a severe bleeding and consumptive microangiopathy connected with organ ischemia.

Keywords: thrombocytopenic purpura; bleeding; platelets; consumptive microangiopathy

Received: March 15, 2005; Accepted: March 15, 2005; Published: July 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Salaj P. Thrombocytopenic purpuras. Vnitr Lek. 2005;51(7-8):854-860.
Download citation

References

  1. Alving BM. How I treat heparin-Induced thrombocytopenia and thrombosis. Blood 2003; 101: 31-37. Go to original source... Go to PubMed...
  2. Ben-Yehuda D, Gillis S, Eldor A. Clinical and therapeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura. Israeli ITP Study Group. Acta Haematol 1994; 91: 1-6. Go to original source... Go to PubMed...
  3. Berchtold P, Wenger M. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: Their clinical significance and response to treatment. Blood 1993; 81: 1246-1250. Go to original source...
  4. Colman RW, Hirsh J, Marder VJ et al. Hemostasis and Thrombosis. 4th Ed. Philadelphia: William and Wilkins 2001.
  5. Furlan M, Robles R, Solenthaler M et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-3103. Go to original source...
  6. Furlan M, Robles R, Solenthaler M et al. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998; 91: 2839-2846. Go to original source...
  7. George JN at al. Idiopathic Thrombocytopenic Purpura: A Practice Guideline Developed by Explicit Methods for the American Society of Hematology. Blood 1996; 88: 3-40. Go to original source...
  8. Nagasawa T, Hasegawa Y, Komeno T et al. Simultaneous measurements of megakaryocyte-associated IgG (MAIgG) and platelet-associated IgG (PAIgG) in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 1995; 54: 314-320. Go to original source... Go to PubMed...
  9. Rock GA. Review: Managemant of thrombotic thrombocytopenic purpura. B J Haem 2000; 109: 496-507. Go to original source... Go to PubMed...
  10. Stasi R, Stipa E, Masi M et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98: 436-442. Go to original source... Go to PubMed...
  11. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.